Guerin, Mathilde <br/><br/>
[Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers].  [electronic resource] 

 -  Bulletin du cancer  Apr 2015 
 - 390-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1769-6917 
<br/><br/><label>Standard No.: </label>10.1016/j.bulcan.2015.02.007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Ado-Trastuzumab Emtansine<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Clinical Trials, Phase III as Topic<br/>Drug Approval<br/>Female<br/>Humans<br/>Maytansine--analogs & derivatives<br/>Neoplasm Proteins--metabolism<br/>Randomized Controlled Trials as Topic<br/>Receptor, ErbB-2--metabolism<br/>Trastuzumab